Genscript Biotech Corporation (G51) - Total Liabilities

Latest as of June 2025: €1.01 Billion EUR ≈ $1.18 Billion USD

Based on the latest financial reports, Genscript Biotech Corporation (G51) has total liabilities worth €1.01 Billion EUR (≈ $1.18 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Genscript Biotech Corporation generate cash to assess how effectively this company generates cash.

Genscript Biotech Corporation - Total Liabilities Trend (2016–2024)

This chart illustrates how Genscript Biotech Corporation's total liabilities have evolved over time, based on quarterly financial data. Check G51 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Genscript Biotech Corporation Competitors by Total Liabilities

The table below lists competitors of Genscript Biotech Corporation ranked by their total liabilities.

Company	Country	Total Liabilities
Valeo SA PA:FR	France	€16.42 Billion
ZF Commercial Vehicle Control Systems India Limited NSE:ZFCVINDIA	India	Rs6.01 Billion
Metro Brands Limited NSE:METROBRAND	India	Rs19.36 Billion
Marex Group plc Ordinary Shares NASDAQ:MRX	USA	$31.76 Billion
Standex International Corporation NYSE:SXI	USA	$809.75 Million
Chengdu Xingrong Investment Co Ltd SHE:000598	China	CN¥28.47 Billion
AIR CHINA LTD H ADR/20 F:AD2B	Germany	€303.82 Billion
Virbac SA PA:VIRP	France	€750.28 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Genscript Biotech Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see G51 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.96	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genscript Biotech Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genscript Biotech Corporation (2016–2024)

The table below shows the annual total liabilities of Genscript Biotech Corporation from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€954.91 Million ≈ $1.12 Billion	-28.89%
2023-12-31	€1.34 Billion ≈ $1.57 Billion	+13.45%
2022-12-31	€1.18 Billion ≈ $1.38 Billion	+3.85%
2021-12-31	€1.14 Billion ≈ $1.33 Billion	+80.40%
2020-12-31	€631.82 Million ≈ $738.66 Million	+22.18%
2019-12-31	€517.11 Million ≈ $604.56 Million	+22.05%
2018-12-31	€423.68 Million ≈ $495.32 Million	+53.54%
2017-12-31	€275.94 Million ≈ $322.61 Million	+556.84%
2016-12-31	€42.01 Million ≈ $49.12 Million	--

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$3.76 Billion

€3.21 Billion EUR

Market Cap Rank

#4914 Global

#816 in Germany

Share Price

€1.47

Change (1 day)

+0.68%

52-Week Range

€1.14 - €2.04

All Time High

€4.62